Modeling drug action in the mouse with knockouts and RNA interference

Drug Discovery Today: TARGETS

Volumn 3, Issue 5, 2004, Pages 198-207

  Zambrowicz, Brian P ^a   Sands, Arthur T ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Biochemistry; chemical genomics; drug discovery; Drug Discovery; Genetics; knockout; modeling; Pharmaceutical Science; RNA interference

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RNA;

CHEMICAL GENETICS; DRUG ACTIVITY; DRUG INDUSTRY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; GENOME; GENOME ANALYSIS; HOST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; KNOCKOUT MOUSE; MAMMAL; METABOLIC SYNDROME X; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PREDICTION; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS; SPECIES COMPARISON; TECHNIQUE; VALIDATION PROCESS;

EID: 4644229134     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1741-8372(04)02454-5     Document Type: Review

References (83)

1. The fruits of genomics: drug pipelines face indigestion until the new biology ripens. 2001;110 Lehman Brothers, McKinsey and Company
2. Lindsay M.A. Target Discovery. Nat. Rev. Drug Discov. 2:2003;831-838
3. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1:2002;727-730
4. Grimmond S.M., et al. The mouse secretome: functional classification of the proteins secreted into the extracellular environment. Genome Res. 13:2003;1350-1359
5. Strausberg R.L., Schreiber S.L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science. 300:2003;294-295
6. Salemme F.R. Chemical genomics as an emerging paradigm for postgenomic drug discovery. Pharmacogenomics. 4:2003;257-267
7. Zheng X.F., Chan T.F. Chemical genomics: a systematic approach in biological research and drug discovery. Curr. Issues Mol. Biol. 4:2002;33-43
8. Capecchi M.R. Altering the genome by homologous recombination. Science. 244:1989;1288-1292
9. Friedrich G., Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5:1991;1513-1523
10. Skarnes W.C., et al. A gene trap approach in mouse embryonic stem cells: the lacZ reported is activated by splicing, reflects endogenous gene expression, and is mutagenic in mice. Genes Dev. 6:1992;903-918
11. Zambrowicz B.P., Friedrich G.A. Comprehensive mammalian genetics: history and future prospects of gene trapping in the mouse. Int. J. Dev. Biol. 42:1998;1025-1036
12. Zambrowicz B.P., et al. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc. Natl. Acad. Sci. U.S.A. 100:2003;14109-14114
13. Zambrowicz B.P., Sands A.T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2:2003;38-51
14. Zambrowicz B.P., et al. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr. Opin. Pharmacol. 3:2003;563-570
15. Ito M., et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc. Natl. Acad. Sci. U.S.A. 92:1995;3521-3525
16. Sugaya T., et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270:1995;18719-18722
17. Esther C.R. Jr, et al. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab. Invest. 74:1996;953-965
18. Krege J.H., et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature. 375:1995;146-148
19. Lu B., et al. The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat. Med. 3:1997;904-907
20. Yanai K., et al. Renin-dependent cardiovascular functions and renin-independent blood - brain barrier functions revealed by renin-deficient mice. J. Biol. Chem. 275:2000;5-8
21. Berger S., et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9424-9429
22. Yun J., et al. Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene. J. Clin. Invest. 106:2000;1361-1371
23. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 414:2001;821-827
24. Ohashi K., et al. Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene. J. Biol. Chem. 278:2003;42936-42941
25. Miles P.D., et al. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105:2000;287-292
26. Bockamp E., et al. Of mice and models: improved animal models for biomedical research. Physiol. Genomics. 11:2002;115-132
27. Hevener A.L., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9:2003;1491-1497
28. Schmidt E.E., et al. Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13702-13707
29. Shokat K., Velleca M. Novel chemical genetic approaches to the discovery of signal transduction inhibitors. Drug Discov. Today. 7:2002;872-879
30. Dykxhoorn D.M., et al. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4:2003;457-467
31. Fire A., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:1998;806-811
32. Wianny F., Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat. Cell Biol. 2:2000;70-75
33. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498
34. Zender L., et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U.S.A. 100:2003;7797-7802
35. Kunath T., et al. Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 21:2003;559-561
36. Rubinson D.A., et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33:2003;401-406
37. Tiscornia G., et al. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. U.S.A. 100:2003;1844-1848
38. Hemann M.T., et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33:2003;396-400
39. Bridge A.J., et al. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34:2003;263-264
40. Sledz C.A., et al. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:2003;834-839
41. Jackson A.L., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21:2003;635-637
42. Scacheri P.C., et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 101:2004;1892-1897
43. Matsukura S., et al. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 31:2003;e77
44. Wiznerowicz M., Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77:2003;8957-8961
45. Fraser A.G., et al. Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature. 408:2000;325-330
46. Kamath R.S., et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature. 421:2003;231-237
47. Kamath R.S., Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods. 30:2003;313-321
48. Hannon G.J. RNA interference. Nature. 418:2002;244-251
49. Zheng L., et al. An approach to genome-wide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 101:2004;135-140
50. Arts G-J., et al. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res. 13:2003;2325-2332
51. Hrabe de Angelis M.H., et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat. Genet. 25:2000;444-447
52. Nolan P.M., et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat. Genet. 25:2000;440-443
53. Parker J.C., et al. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290:2002;839-843
54. Gelling R.W., et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100:2003;1438-1443
55. Lei K.J., et al. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse. Nat. Genet. 13:1996;203-209
56. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology. 142:2001;521-527
57. Miyawaki K., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96:1999;14843-14847
58. Miyawaki K., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8:2002;738-742
59. Marguet D., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6874-6879
60. Conarello S.L., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 100:2003;6825-6830
61. Kitamura T., et al. Insulin receptor knockout mice. Annu. Rev. Physiol. 65:2003;313-332
62. Bluher M., et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell. 3:2002;25-38
63. Elchebly M., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283:1999;1544-1548
64. Hoeflich K.P., et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406:2000;86-90
65. Clement S., et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature. 409:2001;92-97
66. Yuan M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 293:2001;1673-1677
67. Huszar D., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141
68. Shimano H., et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274:1999;35832-35839
69. Shimano H. Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc. Med. 10:2000;275-278
70. Viollet B., et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111:2003;91-98
71. Viollet B., et al. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans. 31:2003;216-219
72. Abu-Elheiga L., et al. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 291:2001;2613-2616
73. Abu-Elheiga L., et al. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc. Natl. Acad. Sci. U.S.A. 100:2003;10207-10212
74. Kubota N., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277:2002;25863-25866
75. Maeda N., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8:2002;731-737
76. Kersten S., et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103:1999;1489-1498
77. Guerre-Millo M., et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 50:2001;2809-2814
78. Sugden M.C., et al. Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem. J. 364:2002;361-368
79. Peters J.M., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J. Biol. Chem. 272:1997;27307-27312
80. Costet P., et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273:1998;29577-29585
81. Steppan C.M., et al. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312
82. Kotelevtsev Y., et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 94:1997;14924-14929
83. Morton N.M., et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276:2001;41293-41300